• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Investigation for the roles of IL-17/LL37 signaling in melanoma

Research Project

Project/Area Number 21K08318
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53050:Dermatology-related
Research InstitutionTohoku University

Principal Investigator

FUJIMURA TAKU  東北大学, 医学系研究科, 准教授 (50396496)

Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2023: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2022: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2021: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywordsメラノーマ / 腫瘍内免疫環境 / LL-37 / 腫瘍随伴性マクロファージ / 皮膚がん / 有棘細胞癌 / IL-17シグナル / 発癌・腫瘍進行 / 血管新生因子 / MMP-9 / 炎症性サイトカイン / LL37 / 局所浸潤 / 血管新生形式 / MMP9 / VEGF-C / 悪性黒色腫 / IL-17/LL37シグナル
Outline of Research at the Start

本研究は、IL-17/ LL37シグナルが悪性黒色腫の腫瘍の進行に与える影響を、腫瘍随伴性マクロファージ(Tumor-associated macrophages: TAMs)を中心に解析することを主な目的とする。この度我々は、1)黒色腫真皮内のmyeloid 細胞におけるLL37の発現が、黒色腫腫瘍環境に与える影響をマウス黒色腫モデルとヒト単球由来のM2マクロファージを用いて検討すること、2)現在、炎症性皮膚疾患で承認されている抗IL-17抗体や抗IL-23抗体が黒色腫の腫瘍免疫に与える影響を検証することを目的とする。

Outline of Final Research Achievements

In this study, LL-37 in tumours increases in the proportion of positive cells in proportion to the tumour depth of malignant melanoma, LL-37-positive cells in tumours are vascular endothelial cells and macrophages, and LL-37 is also abundant around melanoma cells, indicating that LL-37 can act on these cells The study revealed that LL-37 can act on these cells. We also showed that LL-37 enhances the production of angiogenic factors (MMP-9, CXCL5, IL-23p19) in tumour cells themselves and subsequently promotes tumour angiogenesis in the mouse B17F10 model. These series of results were published in the European English-language journal Cancers in 2023.

Translated with DeepL.com (free version)

Academic Significance and Societal Importance of the Research Achievements

本研究ではIL-17/ LL-37シグナルがメラノーマのみならず有棘細胞癌においても、腫瘍の進行に関与する因子であることを明らかにした。メラノーマの局所浸潤度(腫瘍の厚さ)はメラノーマ患者の生命予後に直接的に影響を与える重要因子であることから、本研究によりIL-17/ LL-37シグナルがメラノーマの予後に関わる重要因子であることが示唆された。抗IL-17抗体は、炎症性皮膚疾患で臨床現場で幅広い疾患に使用されていることから本研究が悪性黒色腫をはじめとする皮膚がん全般に与える影響は大きい。今後、臨床試験を開始、これら基礎データを還元することで本研究は増え続ける皮膚がんの治療に大きな影響を与える。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (56 results)

All 2024 2023 2022 2021

All Journal Article (25 results) (of which Int'l Joint Research: 4 results,  Peer Reviewed: 25 results,  Open Access: 14 results) Presentation (31 results) (of which Int'l Joint Research: 8 results,  Invited: 9 results)

  • [Journal Article] Radiation-induced cutaneous squamous cell carcinoma showing a significant response to pembrolizumab: A case report.2024

    • Author(s)
      Takahashi-Watanabe M, Fujimura T, Amagai R, Ohuchi K, Yamazaki E, Tamabuchi E, Kuroki S, Kambayashi Y, Hashimoto A, Asano Y.
    • Journal Title

      Journal of Dermatology

      Volume: 52

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Possible effects of plasminogen activator inhibitor‐1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides2024

    • Author(s)
      Fujimura Taku、Ohuchi Kentaro、Ikawa Tetsuya、Kambayashi Yumi、Amagai Ryo、Furudate Sadanori、Asano Yoshihide
    • Journal Title

      Hematological Oncology

      Volume: 42 Issue: 1

    • DOI

      10.1002/hon.3244

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Efficacy and safety of <scp>TM5614</scp> in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase <scp>II</scp> study protocol2023

    • Author(s)
      Fujimura Taku、Yoshino Koji、Nakamura Motoki、Kato Hiroshi、Ito Takamichi、Maekawa Takeo、Fujisawa Yasuhiro、Matsushita Shigeto、Amagai Ryo、Yamazaki Emi、Takahashi Manami、Tamabuchi Erika、Hashimoto Akira、Kambayashi Yumi、Yamazaki Naoya、Miyata Toshio、Asano Yoshihide
    • Journal Title

      Experimental Dermatology

      Volume: 33 Issue: 1

    • DOI

      10.1111/exd.14976

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Adverse events associated with postoperative outcomes of adjuvant <scp>anti‐PD</scp>‐1 antibody therapy in both acral and non‐acral cutaneous melanomas: A multicenter, observational, post hoc analysis study2023

    • Author(s)
      Muto Yusuke、Kambayashi Yumi、Kato Hiroshi、Fukushima Satoshi、Ito Takamichi、Maekawa Takeo、Fujisawa Yasuhiro、Yoshino Koji、Uchi Hiroshi、Matsushita Shigeto、Yamamoto Yuki、Amagai Ryo、Ohuchi Kentaro、Hashimoto Akira、Asano Yoshihide、Fujimura Taku
    • Journal Title

      The Journal of Dermatology

      Volume: 51 Issue: 3 Pages: 458-462

    • DOI

      10.1111/1346-8138.16912

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab2023

    • Author(s)
      Amagai Ryo、Fujimura Taku、Kambayashi Yumi、Ohuchi Kentaro、Yamazaki Emi、Hashimoto Akira、Asano Yoshihide
    • Journal Title

      Case Reports in Oncology

      Volume: 16 Issue: 1 Pages: 1490-1493

    • DOI

      10.1159/000534657

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Postoperative adjuvant therapy for 120?patients with melanoma, including acral and mucosal subtypes: a multicentre, observational study of 2-year follow-up results2023

    • Author(s)
      Muto Yusuke、Kambayashi Yumi、Kato Hiroshi、Fukushima Satoshi、Ito Takamichi、Maekawa Takeo、Shoichiro Ishizuki、Uchi Hiroshi、Matsushita Shigeto、Yamamoto Yuki?、Yoshino Koji、Fujisawa Yasuhiro?、Amagai Ryo、Ohuchi Kentaro?、Hashimoto Akira、Asano Yoshihide?、Fujimura Taku
    • Journal Title

      British Journal of Dermatology

      Volume: 189 Issue: 4 Pages: 476-478

    • DOI

      10.1093/bjd/ljad183

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Acquired idiopathic generalized anhidrosis followed by COVID-19 infection.2023

    • Author(s)
      4.Mikami Y, Fujimura T, Chiba H, Yamazaki E, Hacchome N, Omori-Shimada R, Takahashi T, Asano Y.
    • Journal Title

      Journal of Dermatology

      Volume: in press Issue: 8 Pages: 245-246

    • DOI

      10.1111/1346-8138.16771

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases.2023

    • Author(s)
      Fujimura T, Maekawa T, Kato H, Ito T, Matsushita S, Yoshino K, Hashimoto A, Fujisawa Y, Ishizuki S, Segawa K, Yamamoto J, Hashimoto A, Kambayashi Y, Asano Y.
    • Journal Title

      Journal of Dermatology

      Volume: in press Issue: 7 Pages: 912-916

    • DOI

      10.1111/1346-8138.16786

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] LL-37 might promote local invasion of melanoma by activating melanoma cells and tumor-associated macrophages.2023

    • Author(s)
      2.Ohuchi K, Ikawa T, Amagai R,Takahashi T, Roh Y, Endo J, Kambayashi Y, Asano Y, Fujimura T.
    • Journal Title

      Cancers

      Volume: 15 Issue: 6 Pages: 1678-1678

    • DOI

      10.3390/cancers15061678

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] An antimicrobial peptide cathelicidin passes mainly scavenger receptors.2023

    • Author(s)
      Amagai R, Takahashi T, Terui H, Fujimura T, Yamasaki K, Aiba S, Asano Y.
    • Journal Title

      International Journal of Molecular Science.

      Volume: 24 Issue: 1 Pages: 875-875

    • DOI

      10.3390/ijms24010875

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases.2023

    • Author(s)
      Fujimura T, Furudate S, Maekawa T, Kato H, Ito T, Matsushita S, Yoshino K, Hashimoto A, Muto Y, Ohuchi K, Amagai R, Kambayashi Y, Fujisawa Y.
    • Journal Title

      Skin Health and Disease

      Volume: 3 Issue: 1

    • DOI

      10.1002/ski2.180

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Plasminogen activating inhibitor-1 promotes angiogenesis in cutaneous angiosarcomas.2023

    • Author(s)
      Ohuchi K, Amagai R, Ikawa T, Muto Y, Roh Y, Endo J, Maekawa T, Kambayashi Y, Asano Y, Fujimura T.
    • Journal Title

      Experimental Dermatology

      Volume: 32 Issue: 1 Pages: 50-59

    • DOI

      10.1111/exd.14681

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Immunotherapy for melanoma: the significance of immune checkpoints inhibitors for the treatment of advanced melanoma.2022

    • Author(s)
      Fujimura T, Muto Y, Asano Y.
    • Journal Title

      International Journal of Molecular Science.

      Volume: 23 Issue: 24 Pages: 15720-15720

    • DOI

      10.3390/ijms232415720

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Serum CCL22 increased in advanced melanoma patients with liver metastase: report of 5 cases.2022

    • Author(s)
      Ohuchi K, Amagai R, Kambayashi Y, Asano Y, Fujimura T.
    • Journal Title

      Case Reports in Oncology

      Volume: 15 Issue: 3 Pages: 1114-1120

    • DOI

      10.1159/000528328

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] New onset of palmoplantar keratosis triggered by COVID-19 vaccination.2022

    • Author(s)
      Itabashi C, Ohuchi K, Roh Y, Asano Y, Fujimura T.
    • Journal Title

      Dermatologic Therapy

      Volume: 35 Issue: 12

    • DOI

      10.1111/dth.15937

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Cutaneous T-cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series.2022

    • Author(s)
      Amagai R, Kambayashi Y, Ohuchi K, Furudate S, Hashimoto A, Asano Y, Fujimura T.
    • Journal Title

      Dermatologic Therapy

      Volume: 35 Issue: 11

    • DOI

      10.1111/dth.15858

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.2022

    • Author(s)
      Kambayashi Y, Kasahara Y, Ohuchi K, Amagai R, Hashimoto A, Asano Y, Fujimura T.
    • Journal Title

      Dermatologic Therapy

      Volume: 35 Issue: 10

    • DOI

      10.1111/dth.15736

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases.2022

    • Author(s)
      Muto Y, Kambayashi Y, Kato H, Fukushima S, Ito T, Maekawa T, Fujisawa Y, Yoshino K, Uchi H, Matsushita S, Yamamoto Y, Amagai R, Ohuchi K, Hashimoto A, Fujimura T.
    • Journal Title

      Acta DermatoVenereologica

      Volume: in press Pages: 00756-00756

    • DOI

      10.2340/actadv.v102.678

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers.2022

    • Author(s)
      Fujimura T
    • Journal Title

      International Journal of Molecular Science.

      Volume: 23 Issue: 7 Pages: 4044-4044

    • DOI

      10.3390/ijms23074044

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy2022

    • Author(s)
      Ohuchi Kentaro、Amagai Ryo、Tamabuchi Erika、Kambayashi Yumi、Fujimura Taku
    • Journal Title

      The Journal of Dermatology

      Volume: - Issue: 5

    • DOI

      10.1111/1346-8138.16304

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases.2021

    • Author(s)
      Amagai R, Muto Y, Kato H, Matsushita S, Maekawa T, Fukushima S, Yoshino K, Uchi H, Fujisawa Y, Yamamoto Y, Ohuchi K, Kambayashi Y, Fujimura T.
    • Journal Title

      Melanoma Research

      Volume: 31 Issue: 6 Pages: 575-578

    • DOI

      10.1097/cmr.0000000000000770

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients.2021

    • Author(s)
      Ohuchi K, Kambayashi Y, Hidaka T, Fujimura T
    • Journal Title

      Front Oncology

      Volume: 11 Pages: 798385-798385

    • DOI

      10.3389/fonc.2021.798385

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Phosphor-signal transducers and activator of transcription 1 signaling in mucosal lichen planus developing from metastatic bladder cancer treated with pembrolizumab.2021

    • Author(s)
      Tamabuchi E, Fujimura T, Lyu C, Aiba S.
    • Journal Title

      Dermatologic Therapy

      Volume: 34 Issue: 4

    • DOI

      10.1111/dth.14961

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Successful treatment of BRAF/MEK inhibitor‐resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity‐modulated radiotherapy2021

    • Author(s)
      Okuma Takami、Furudate Sadanori、Kambayashi Yumi、Hashimoto Akira、Aiba Setsuya、Fujimura Taku
    • Journal Title

      The Journal of Dermatology

      Volume: 48 Issue: 9 Pages: 1419-1422

    • DOI

      10.1111/1346-8138.15962

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report2021

    • Author(s)
      Amagai Mayuko、Ozawa Maki、Amagai Ryo、Ohuchi Kentaro、Muto Yusuke、Kambayashi Yumi、Aiba Setsuya、Fujimura Taku
    • Journal Title

      Dermatologic Therapy

      Volume: 35 Issue: 3

    • DOI

      10.1111/dth.15290

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Presentation] Nivolumab plus PAI-1 inhibitor combined therapy for unresectable advanced melanoma: phase II clinical trial.2023

    • Author(s)
      Taku Fujimura, Koji Yoshino, Hiroshi Kato, Satoshi Fukushima, Atsushi Otsuka, Shigeto Matsushita , Yasuhiro Fujisawa, Shoichiro Ishizuki, Yumi Kambayashi , Yoshihide Asano
    • Organizer
      1st International Society for Investigative Dermatology Meeting
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Development of novel targeting therapy for pro-angiogenesis factor in cutaneous angiosarcomas2023

    • Author(s)
      Kentaro Ohuchi, Taku Fujimura, Tetsuya Ikawa, Ryo Amagai, Takeo Maekawa, Yumi Kambayashi, Yoshihide Asano
    • Organizer
      1st International Society for Investigative Dermatology Meeting
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] メラノーマの術後補助療法:海外エビデンスと本邦における位置づけ2023

    • Author(s)
      藤村卓
    • Organizer
      第122回日本皮膚科学会総会
    • Related Report
      2023 Annual Research Report
    • Invited
  • [Presentation] タキサン系抗がん剤無効皮膚血管肉腫に対するセカンドライン化学療法の検証:多施設共同研究2023

    • Author(s)
      藤村卓、前川武雄、伊東孝通、加藤裕史、松下茂人、吉野公二、藤澤康弘、神林由美、橋本彰、浅野善英
    • Organizer
      第122回日本皮膚科学会総会
    • Related Report
      2023 Annual Research Report
  • [Presentation] BRAF変異メラノーマに対するエンコラフェニブ・ビニメチニブ療法の有効性・安全性の検証2023

    • Author(s)
      日渡早紀、藤村卓、神林由美、玉渕恵里佳、千葉広夢、天貝 諒、大内謙太郎、神林由美、橋本彰、浅野善英
    • Organizer
      第122回日本皮膚科学会総会
    • Related Report
      2023 Annual Research Report
  • [Presentation] 再発性/難治性CTCLの治療におけるデニロイキン・ジフチトクスの役割2023

    • Author(s)
      藤村卓
    • Organizer
      第39回日本皮膚悪性腫瘍学会
    • Related Report
      2023 Annual Research Report
    • Invited
  • [Presentation] 進行性悪性黒色腫治療におけるニボルマブ・PAI-1阻害薬併用療法の安全性・有効性の検討2023

    • Author(s)
      藤村卓、吉野公二、加藤裕史、福島聡、藤澤康弘、石月翔一郎、大塚篤司、松下茂人、神林由美、浅野善英
    • Organizer
      第39回日本皮膚悪性腫瘍学会
    • Related Report
      2023 Annual Research Report
  • [Presentation] メラノーマ抗PD-1抗体術後補助療法:irAEが予後に与える影響の検討2023

    • Author(s)
      武藤雄介、藤村卓、加藤裕史、福島聡、伊東孝通、前川武雄、藤澤康弘、吉野公二、松下茂人、浅野善英
    • Organizer
      第39回日本皮膚悪性腫瘍学会
    • Related Report
      2023 Annual Research Report
  • [Presentation] 当科における進行期メラノーマに対するニボルマブ+イピリムマブ併用療法の治療経験2023

    • Author(s)
      天貝諒、藤村卓、板橋 知怜、神林由美、大内謙太郎、千葉広夢、玉渕恵里佳、橋本彰、浅野善英
    • Organizer
      第39回日本皮膚悪性腫瘍学会
    • Related Report
      2023 Annual Research Report
  • [Presentation] 菌状息肉腫の治療:進行期移行期に選択すべき薬剤は?2023

    • Author(s)
      藤村卓
    • Organizer
      第87回日本皮膚科学会東部支部学術大会
    • Related Report
      2023 Annual Research Report
    • Invited
  • [Presentation] 若年女性の腹部皮膚に生じたCIC-DUX4肉腫の1例2023

    • Author(s)
      天貝諒、藤村卓、吉田 新一郎、浅野 善英
    • Organizer
      第87回日本皮膚科学会東部支部学術大会
    • Related Report
      2023 Annual Research Report
  • [Presentation] R-CHOP療法による色素沈着型薬疹の1例2023

    • Author(s)
      山本惇、藤村卓、小野寺晃一、浅野善英
    • Organizer
      第87回日本皮膚科学会東部支部学術大会
    • Related Report
      2023 Annual Research Report
  • [Presentation] 基礎から考えるCTCL治療アルゴリズム:早期から進行期にかけて選択すべき薬剤は?2023

    • Author(s)
      藤村卓
    • Organizer
      第74回日本皮膚科学会東部支部学術大会
    • Related Report
      2023 Annual Research Report
    • Invited
  • [Presentation] BRAF/MEK阻害薬の使用に関連しVogt-小柳-原田病様ぶどう膜炎を生じた5例のHLAタイプの検討2023

    • Author(s)
      天貝 諒、藤村 卓、山﨑 絵美、玉渕 恵里佳、神林 由美、橋本 彰、浅野 善英
    • Organizer
      第74回日本皮膚科学会東部支部学術大会
    • Related Report
      2023 Annual Research Report
  • [Presentation] ペムブロリズマブが著効したCD8+ syringotropic菌状息肉症に発症した放射線誘発有棘細胞癌の1例2023

    • Author(s)
      髙橋愛美、藤村卓、天貝諒、大内謙太郎、神林由美、橋本彰、浅野善英
    • Organizer
      第87回日本皮膚科学会東部支部学術大会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Development of novel anti-PD-1 Abs based immunotherapy for unresectable advanced melanoma: phase II clinical trial.2023

    • Author(s)
      Taku Fujimura
    • Organizer
      第45回日本血栓止血学会
    • Related Report
      2023 Annual Research Report
    • Invited
  • [Presentation] 進行期メラノーマに対するニボルマブ・PAI-1阻害薬併用療法の安全性・有効性の検討2022

    • Author(s)
      藤村卓、吉野公二、加藤裕史、福島聡、大塚篤司、松下茂人、神林由美、橋本彰、藤澤康弘
    • Organizer
      第120回 日本皮膚科学会総会
    • Related Report
      2022 Research-status Report
  • [Presentation] 抗PD-1抗体によるメラノーマ術後補助療法の有効性・安全性の検証:多施設共同研究2022

    • Author(s)
      武藤雄介、加藤裕史、福島聡、伊東孝通、前川武雄、藤澤康弘、吉野公二、 内 博史、松下茂人、藤村卓
    • Organizer
      第120回 日本皮膚科学会総会
    • Related Report
      2022 Research-status Report
  • [Presentation] 皮膚T細胞性リンパ腫に対するモガムリズマブ療法:11例の後ろ向き解析2022

    • Author(s)
      天貝 諒、神林由美、大内謙太郎、古舘 禎騎、橋本彰、藤村卓
    • Organizer
      第120回 日本皮膚科学会総会
    • Related Report
      2022 Research-status Report
  • [Presentation] BRAF変異陽性悪性黒色腫に対する集学的治療―BRAF/MEK阻害薬使用最適化への試みー2022

    • Author(s)
      藤村卓
    • Organizer
      第38回日本皮膚悪性腫瘍学会
    • Related Report
      2022 Research-status Report
    • Invited
  • [Presentation] 皮膚科領域における癌ゲノムパネル検査の可能性2022

    • Author(s)
      藤村卓
    • Organizer
      第38回日本皮膚悪性腫瘍学会
    • Related Report
      2022 Research-status Report
    • Invited
  • [Presentation] 骨髄癌腫症を呈した悪性黒色腫の1例;本邦報告例のまとめ2022

    • Author(s)
      神林由美、髙橋隼也、橋本彰、藤村卓、市川聡
    • Organizer
      第38回日本皮膚悪性腫瘍学会
    • Related Report
      2022 Research-status Report
  • [Presentation] ベキサロテンで加療した未分化大細胞リンパ腫の3例2022

    • Author(s)
      大内謙太郎、天貝 諒、大熊崇生、千葉広夢、玉渕恵里佳、古舘禎騎、神林由美、橋本 彰、藤村 卓
    • Organizer
      第38回日本皮膚悪性腫瘍学会
    • Related Report
      2022 Research-status Report
  • [Presentation] タキサン系抗がん剤で加療した皮膚血管肉腫の治療経験:15例の後ろ向き解析2022

    • Author(s)
      古舘禎騎、天貝 諒、大内謙太郎、大熊崇生、千葉広夢、玉渕恵里佳、神林由美、橋本 彰、藤村 卓
    • Organizer
      第38回日本皮膚悪性腫瘍学会
    • Related Report
      2022 Research-status Report
  • [Presentation] Pro-angiogenic factors might predict the efficacy of bexarotene in advanced cutaneous T cell lymphomas2022

    • Author(s)
      Yumi Kambayashi, Taku Fujimura, Kentaro Ohuchi, Ryo Amagai, Yoshihide Asano
    • Organizer
      第47回日本研究皮膚科学会
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] LL37 might promote local invasion of melanoma by the stimulation of melanoma cells and tumor-associated macrophages2022

    • Author(s)
      Kentaro Ohuchi, Taku Fujimura, Ryo Amagai, Yuna Roh, Junko Endo, Yumi Kambayashi, Yoshihide Asano
    • Organizer
      第47回日本研究皮膚科学会
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] Immunomodulatory and pro-angiogenic effects of plasminogen activating inhibitor-1 in tumor microenvironment of melanoma2022

    • Author(s)
      Airi Kobayashi, Taku Fujimura, Kentaro Ohuchi, Hitoshi Terui, Yumi Kambayashi, Yoshihide Asano
    • Organizer
      第47回日本研究皮膚科学会
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] Development of the combination therapy of anti-PD1 antibody with PAI-1 inhibitors in advanced melanoma patients2022

    • Author(s)
      Taku Fujimura, Kentaro Ohuchi, Yumi Kambayashi, Takanori Hidaka, Yoshihide Asano
    • Organizer
      第51回欧州研究皮膚科学会(European Society for Dermatological Reserch)
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] Plasminogen activating inhibitor-1 could be a key factor for the induction of angiogenesis in cutaneous angiosarcomas2022

    • Author(s)
      Kentaro Ohuchi, Taku Fujimura, Ryo Amagai, Takeo Maekawa, Yumi Kambayashi, Yoshihide Asano
    • Organizer
      第51回欧州研究皮膚科学会(European Society for Dermatological Reserch)
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] 進化する悪性黒色腫の治療:免疫療法の現在と複合免疫療法の開発2021

    • Author(s)
      藤村 卓
    • Organizer
      第37回日本皮膚悪性腫瘍学会
    • Related Report
      2021 Research-status Report
    • Invited
  • [Presentation] Significance of tumor-associated macrophages to predict the efficacy and immune-related adverse events by anti-PD1 antibodies.2021

    • Author(s)
      Taku Fujimura
    • Organizer
      46th Japanese Society for Investigative Dermatology
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research / Invited

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi